Cytokine Production and rIL-2 Therapy in Colorectal Cancer
Author Information
Author(s): D.J. Deehan, S.D. Heys, W.G. Simpson, J. Broom, C. Franks, O. Eremin
Primary Institution: University of Aberdeen
Hypothesis
Can serum cytokine levels predict the response to rIL-2 therapy in patients with advanced colorectal cancer?
Conclusion
Patients with low pretreatment serum IL-6 levels are more likely to respond to rIL-2 therapy.
Supporting Evidence
- Responders had significantly lower pretreatment serum IL-6 and sIL-2R levels than non-responders.
- Only 20-30% of patients with solid tumors responded to rIL-2 therapy.
- High levels of IL-6 during therapy were associated with better responses.
Takeaway
This study found that patients with lower levels of a certain protein in their blood are more likely to get better when treated with a specific cancer therapy.
Methodology
Twenty patients with advanced colorectal cancer were treated with rIL-2, and serum cytokine levels were measured before and during treatment.
Potential Biases
Potential selection bias due to the specific patient population studied.
Limitations
The study only included patients with advanced colorectal cancer, limiting generalizability.
Participant Demographics
20 patients, 10 males and 10 females, age range 36-71 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website